Published • loading... • Updated
Rezera Announces Plans to Launch the REVEAL-PAD Multi-Center Study Investigating the Role of Inflammation in Patients with Peripheral Artery Disease
Summary by Rutland Herald
1 Articles
1 Articles
Rezera Announces Plans to Launch the REVEAL-PAD Multi-Center Study Investigating the Role of Inflammation in Patients with Peripheral Artery Disease
AURORA, CO / ACCESS Newswire / September 22, 2026 / Rezera Inc. (the "Company"), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases, announced plans…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
